Cantor Fitzgerald reiterates Overweight on Ultragenyx, $39 target
Cantor Fitzgerald maintained an Overweight rating on Ultragenyx Pharmaceutical and kept a $39.00 price target, implying 169.0% upside versus the Sep 17 close of $14.50.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.